nct_id: NCT06578247
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-08-29'
study_start_date: '2024-11-19'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Placebo'
  - drug_name: 'Drug: Chemotherapy'
  - drug_name: 'Drug: Quizartinib'
long_title: Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib
  Administered in Combination With Induction and Consolidation Chemotherapy and Administered
  as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative
  Acute Myeloid Leukemia
last_updated: '2025-09-10'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Daiichi Sankyo
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 700
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Key Inclusion Criteria:'
- '* Must be competent and able to comprehend, sign, and date an Ethics Committee
  (EC)- or Institutional Review Board (IRB)-approved Informed Consent Form (ICF) before
  performance of any trial-specific procedures or tests.'
- "* \u226518 years or the minimum legal adult age (whichever is greater) and 70 years\
  \ (at Screening)."
- '* Newly diagnosed, morphologically documented primary AML based on the World Health
  Organization (WHO) 2016 classification (at Screening)'
- '* Eastern Cooperative Oncology Group (ECOG) performance status (at the time the
  participant signs their ICF) of 0-2.'
- '* Participant is receiving standard "7+3" induction chemotherapy regimen as specified
  in the protocol'
- 'Exclude - Key Exclusion Criteria:'
- Exclude - * Diagnosis of acute promyelocytic leukemia (APL), French-American-British
  classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12),
  or BCR-ABL positive leukemia (ie, chronic myelogenous leukemia in blast crisis);
  participants who undergo diagnostic workup for APL and treatment with all-trans
  retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment
  with ATRA must be discontinued before starting induction chemotherapy).
- Exclude - * Diagnosis of AML secondary to prior chemotherapy or radiotherapy for
  other neoplasms or autoimmune/rheumatologic conditions.
- Exclude - * Diagnosis of AML secondary to myelodysplastic syndrome (MDS) or a myeloproliferative
  neoplasm (MPN) or MDS/MPNs including CMML, aCML, JMML and others.
- "Exclude - * Participants with newly diagnosed AML with FLT3-ITD mutations (FLT3-ITD\
  \ \\[+\\]) present at \u22655% VAF (or \u22650.05 SR) based on a validated FLT3\
  \ mutation assay."
- 'Exclude - * Prior treatment for AML, except for the following allowances:'
- Exclude - 1. Leukapheresis;
- Exclude - 2. Treatment for hyperleukocytosis with hydroxyurea;
- Exclude - 3. Cranial radiotherapy for central nervous system (CNS) leukostasis;
- Exclude - 4. Prophylactic intrathecal chemotherapy;
- Exclude - 5. Growth factor/cytokine support.
short_title: Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients
  With FLT3-ITD Negative AML
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Daiichi Sankyo
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This study will compare the effects of Quizartinib versus placebo in combination
  with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase
  3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Arm A: Quizartinib + Chemotherapy'
      arm_internal_id: 0
      arm_description: Participants will receive quizartinib at 60 mg/day orally once
        daily for 14 days starting after the completion of chemotherapy in Induction
        and Consolidation Phase. In the Maintenance Phase, participants will receive
        quizartinib at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Quizartinib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Chemotherapy'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Arm B: Placebo + Chemotherapy'
      arm_internal_id: 1
      arm_description: Participants will receive placebo at 60 mg/day orally once
        daily for 14 days starting after the completion of chemotherapy in Induction
        and Consolidation Phase. In the Maintenance Phase, participants will receive
        placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Placebo'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Chemotherapy'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Arm C: Quizartinib + Chemotherapy then Placebo Maintenance'
      arm_internal_id: 2
      arm_description: Participants will receive quizartinib at 60 mg/day orally once
        daily for 14 days starting after the completion of chemotherapy in Induction
        and Consolidation Phase. In the Maintenance Phase, participants will receive
        placebo at 60 mg/day orally once daily for up to 36 cycles (28-day cycle)
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Quizartinib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Placebo'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Chemotherapy'
        level_internal_id: 2
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Early Stage
          oncotree_primary_diagnosis: Lymphoid Neoplasm
      - and:
        - genomic:
            hugo_symbol: FLT3
            variant_category: '!Mutation'
